Soothing composition for improving skin tolerance and application thereof

Abstract

The invention provides a soothing composition for improving skin tolerance and application of the soothing composition. The composition is prepared from schizandrin A, dihydroquercetin, jonquil glucoside and panthenol. The raw materials in the composition cooperate with each other to synchronously intervene four major pathways of nerve-immunity-blood vessel-barrier, so that the vicious circle of sensitive skin is broken, and the comprehensive effect of quickly relieving symptoms to fundamentally improve the symptoms for a long time is realized.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and more specifically to a soothing composition for improving skin tolerance and its application. Background Technology

[0002] Modern dermatology believes that sensitive skin is not caused by a single factor, but is a complex pathophysiological state caused by a vicious cycle formed by multiple factors, including impaired skin barrier function, hyperresponsiveness of nerves, excessive immune inflammatory response, and capillary dilation. Its core mechanism can be summarized as follows: when physical or chemical factors damage the skin's physical barrier, external stimuli can penetrate more easily, thereby overactivating sensory nerve endings (such as transient receptor potential vanillin type 1, TRPV1) and triggering neurogenic inflammation. This process further recruits and activates immune cells, leading to the release of various inflammatory mediators, causing vasodilation and redness. The persistent inflammatory state, in turn, hinders the normal repair of the skin barrier, ultimately resulting in the skin remaining in a state of hypersensitivity and low tolerance.

[0003] Current mainstream intervention strategies mainly focus on barrier repair (such as supplementing intercellular lipids like ceramides and cholesterol) and anti-inflammatory soothing (such as using dipotassium glycyrrhizate and bisabolol). While these strategies have achieved some success, they also have significant limitations. These approaches struggle to comprehensively cover all four pathways of sensitive skin, particularly lacking precise regulation of sensory nerve overactivation and capillary dilation. This results in limited improvement of core symptoms such as burning, stinging, and persistent redness, and a high recurrence rate. Therefore, developing a multi-target solution that can synergistically act on this complex network has significant demand and market value. Summary of the Invention

[0004] The purpose of this invention is to overcome the shortcomings of the prior art and provide a soothing composition that improves skin tolerance and its application.

[0005] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0006] In a first aspect, the present invention provides a soothing composition comprising the following raw materials: schisandrin A, dihydroquercetin, kaempferol glycoside, and panthenol, wherein the mass ratio of schisandrin A, dihydroquercetin, kaempferol glycoside, and panthenol in the composition is (0.01-3):(0.01-1):(0.01-1):(0.1-5);

[0007] Preferably, the mass ratio of schisandrin A, dihydroquercetin, senna glycoside, and panthenol in the composition is (0.1-1):(0.05-0.5):(0.05-0.5):(0.5-3);

[0008] Preferably, the mass ratio of schisandrin A, dihydroquercetin, senna glycoside, and panthenol in the composition is (0.3-0.5):(0.1-0.5):(0.1-0.2):(1-1.5);

[0009] Preferably, the mass ratio of schisandrin A, dihydroquercetin, senna glycoside, and panthenol in the composition is 0.4:0.15:0.15:1.3.

[0010] Secondly, the present invention provides the application of the soothing composition described in the first aspect in the preparation of cosmetics with soothing and repairing effects.

[0011] Preferably, the cosmetic dosage form is any one of toner, lotion, cream, mask, serum, or spray.

[0012] Thirdly, the present invention provides a lotion with soothing and repairing effects, the lotion comprising the soothing composition described in the first aspect.

[0013] Preferably, the emulsion further includes at least one of a thickener, a humectant, a pH adjuster, an emulsifier, a preservative, and a solvent.

[0014] Preferably, the lotion with soothing and repairing effects comprises the following components by weight percentage:

[0015] The soothing composition described in the first aspect: 1-4%;

[0016] Thickener: 0.05-0.3%;

[0017] Moisturizer: 0.5-3%;

[0018] pH adjuster: 0.01-0.3%;

[0019] Emulsifier: 0.5-5%;

[0020] Preservatives: 0.5-3%;

[0021] Solvent balance.

[0022] Preferably, the thickener comprises at least one of the following: polyacrylate crosspolymer-6, carbomer, carrageenan, gellan gum, xanthan gum, microcrystalline cellulose, cellulose gum, ethyl cellulose, sclerotium taurate gum, guar gum, ammonium acryloyl dimethyl taurate / VP copolymer, acrylate copolymers, and sclerotium taurate gum.

[0023] The moisturizer includes at least one of the following: glycerin, 1,2-butanediol, 1,3-butanediol, 1,2-hexanediol, 1,3-propanediol, caprylyl glycol, dipropylene glycol, tremella polysaccharide, trehalose, betaine, allantoin, sodium hyaluronate, β-glucan, budding stalk polysaccharide, and ceramide.

[0024] The pH adjuster includes at least one of arginine, tromethamine, and disodium EDTA.

[0025] The emulsifier includes at least one of the following: caprylic / capric triglyceride, C14-22 alcohol, C12-20 alkyl glucoside, sodium polyacrylate, hydrogenated lecithin, cetearyl glucoside, isononyl isononanoate, pentaerythritol tetraester, polydimethylsiloxane, stearyl alcohol, hydroxystearic acid, polymethylsilsesquioxane, pentaerythritol distearate, and sucrose stearate.

[0026] The preservative includes at least one of p-hydroxyacetophenone and polyols;

[0027] The solvent is deionized water.

[0028] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0029] This invention utilizes the synergistic effect of four active ingredients to systematically intervene in the pathological process of sensitive skin from four dimensions: neuro-immune-vascular-barrier, forming a full-link repair mechanism of "source regulation - process blocking - structural repair". The specific mechanism is as follows:

[0030] 1. Neural pathway regulation: Inhibiting excessive activation of TRPV1

[0031] Kalanchoe glycosides inhibit TRPV1 expression, reduce the sensitivity of sensory nerve endings to heat, acid, and mechanical stimulation, block the transmission of neurogenic signals such as itching and burning, alleviate nerve hyperresponsiveness, and break the vicious cycle of "stimulus-sensitivity".

[0032] 2. Regulation of immune pathways: Inhibition of inflammatory cascade response

[0033] Dihydroquercetin and schisandrin synergistically regulate inflammatory signaling pathways, inhibiting the release of pro-inflammatory factor (IL-6) and reducing excessive activation of immune cells.

[0034] 3. Vascular access intervention: Stabilizing microvascular status

[0035] Schisandrin A can inhibit redness caused by abnormal dilation of capillaries; dihydroquercetin can regulate the metabolism of inflammatory factors, alleviate increased vascular permeability, and relieve skin flushing; panthenol can enhance vascular elasticity and stability.

[0036] 4. Barrier Pathway Enhancement: Repair the physical defense system

[0037] Kalanchoe glycosides can promote keratinocyte differentiation, enhance FLG expression, and strengthen the stratum corneum network structure; panthenol enhances and repairs the skin barrier function by promoting the synthesis of lipids (such as ceramides) and repairing proteins in skin cells.

[0038] In summary, the four components work synergistically to cover the four major pathological processes of sensitive skin, establishing a positive feedback loop (repairing the barrier to reduce irritant penetration - reducing neuroimmune activation - further promoting barrier repair) to maintain the dynamic balance of the skin's "tolerance-sensitivity" state. Attached Figure Description

[0039] Figure 1 The image shows a comparison of the facial redness area before and after 7 days of use in the blank application example and application example 1 in test example 5. Detailed Implementation

[0040] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Unless otherwise specified, specific conditions in the embodiments are performed under conventional conditions or conditions recommended by the manufacturer. Unless otherwise specified, the components of the formulations in the embodiments are all conventional commercially available products. The following embodiments are further illustrations of the present invention, but not limitations thereof.

[0041] The raw materials used in this invention and their sources are as follows:

[0042] Schisandrin A: Purchased from Shanghai Yuanye Biotechnology Co., Ltd., product number B21326;

[0043] Dihydroquercetin: purchased from Shanghai Yuanye Biotechnology Co., Ltd., product number S28621;

[0044] Longevity flower glycoside: purchased from Sichuan Weikeqi Biotechnology Co., Ltd., product number WKQ-0004512;

[0045] Panthenol: Purchased from Shanghai Yuanye Biotechnology Co., Ltd., product number S11131;

[0046] Unless otherwise specified, the reagents, methods and equipment used in this invention are all conventional reagents, methods and equipment in the field; and unless otherwise specified, the raw materials used in parallel experiments are from the same batch.

[0047] The raw materials, their mass ratios, and preparation methods of the soothing composition are as follows:

[0048] Table 1. Raw materials and their mass ratios for the soothing composition.

[0049] Group Schisandrin A Dihydroquercetin Kalanchoe glycosides Panthenol Example 1 0.4 0.15 0.15 1.3 Example 2 0.5 0.2 0.2 1.5 Example 3 0.3 0.1 0.1 1 Example 4 1 0.05 0.5 0.5 Example 5 0.1 0.5 0.05 3 Example 6 3 0.01 1 0.1 Example 7 0.01 1 0.01 5 Comparative Example 1 0 0.15 0.15 1.3 Comparative Example 2 0.4 0 0.15 1.3 Comparative Example 3 0.4 0.15 0 1.3 Comparative Example 4 0.4 0.15 0.15 0 Comparative Example 5 4 0.005 2 0.05

[0050] In Table 1, the total mass fraction of each raw material in the compositions of Examples 1-7 and Comparative Examples 1-5 is 100 parts.

[0051] The method for preparing the soothing composition provided in Example 1 is as follows: Mix all components evenly to obtain the soothing composition.

[0052] The preparation methods of the soothing compositions in Examples 2-7 and Comparative Examples 1-5 are consistent with those in Example 1.

[0053] The present invention provides an application example and a comparative application example of a lotion with soothing and repairing effects. The components (mass percentage) of the lotion are shown in Table 2. The soothing compositions used in application examples 1-7 are the soothing compositions prepared in examples 1-7, and the soothing compositions used in application examples 8-9 are the soothing compositions prepared in example 1. The soothing compositions used in comparative application examples 1-5 are the soothing compositions prepared in comparative examples 1-5. A blank application example is also provided, the only difference between the blank application example and application example 1 being that no soothing composition is added.

[0054] Table 2. Raw materials and their mass percentage for lotions with soothing and repairing effects.

[0055]

[0056]

[0057] The preparation method of the above-mentioned lotion with soothing and repairing effects includes the following steps:

[0058] (1) Mix the humectant, thickener and EDTA-disodium with deionized water and stir. Heat to 85°C and homogenize at 1300 rpm for 4 min. After homogenization, keep warm for later use to obtain the pre-prepared phase A.

[0059] (2) Mix the emulsifier, heat to 75°C, and homogenize at 1300 rpm for 4 min. After homogenization, keep warm for later use to obtain the pre-prepared phase B.

[0060] (3) Mix the preservatives and heat to 60°C to melt them to obtain the pre-prepared C phase;

[0061] (4) Heat the pre-prepared phase A to 80°C, add the pre-prepared phase B at 300 rpm, stir and mix, then cool down to 60°C, add the pre-prepared phase C at 300 rpm and stir and mix, then cool down to 45°C, add the soothing composition and continue stirring for 8 minutes, finally add the remaining pH adjuster (arginine) to adjust the pH, then stop stirring, discharge the material, and obtain the emulsion.

[0062] Effect Experiment

[0063] Test Example 1: Cellular experiments demonstrated that the composition has the effect of reducing skin sensitivity.

[0064] Test samples: Examples 1-7, Comparative Examples 1-5.

[0065] Experimental Methods: The cell line used was HaCaT (Beina Biotechnology), an immortalized human epidermal cell line. The testing conditions were: incubator temperature 37±1℃, humidity 90±5%, carbon dioxide 5±1%. Cells were cultured and treated according to groups, followed by testing. The specific test was the detection of TRPV1 content, and the testing method is as follows:

[0066] The cell suspension was seeded into 96-well cell culture plates at a density of 2000 cells / well. 100 μL of DMEM medium (2105341, Gibco) was added to each well and the cells were cultured for 24 h.

[0067] Discard the liquid in the wells. Add 100 μL of DMEM medium containing 5 μg / mL capsaicin to the control group and 100 μL of DMEM medium containing 5 μg / mL capsaicin and 0.005 wt% of the test sample to the sample groups, respectively. Each group has 6 parallel replicates and is cultured for 24 h.

[0068] Collect cells from each group, discard the supernatant, lyse the cells with RIPA lysis buffer containing protease inhibitor (Shanghai Merck, V900854), centrifuge the lysed sample at 12000g for 5 minutes, and take the supernatant for subsequent experiments.

[0069] TRPV1 expression detection: The TRPV1 protein level in the cell supernatant of each group was detected using the Human Transforming Receptor Potential Cation Channel Subfamily V Member 1 (TRPV1) ELISA Kit (Shanghai Enzyme-Linked Biotechnology, ml106587). Specifically, equal amounts of supernatant were added to the corresponding reaction wells of the kit. After incubation, washing, and color development, the absorbance (OD) value was measured at a specific wavelength using an ELISA reader. The TRPV1 content of each group was calculated based on the standard curve.

[0070] The skin sensitivity-reducing ability of the composition is expressed by the improvement in TRPV1, as shown in the following formula:

[0071] TRPV1 improvement rate / % = TRPV1 content in sample group / TRPV1 content in control group × 100% - 1;

[0072] The results are shown in Table 3.

[0073] Table 3. Effect of Examples and Comparative Examples on TRPV1 Improvement Rate

[0074] Group TRPV1 improvement rate / % Example 1 63.4 Example 2 62.3 Example 3 59.7 Example 4 58.2 Example 5 52.4 Example 6 50.7 Example 7 43.1 Comparative Example 1 25.1 Comparative Example 2 24.7 Comparative Example 3 13.5 Comparative Example 4 31.6 Comparative Example 5 34.3

[0075] According to the results in Table 3, comparing the results of Examples 1-7, it can be seen that the combined use of schisandrin A, dihydroquercetin, senna glycoside, and panthenol in this invention can improve the TRPV1 improvement rate. Comparing the results of Example 1 and Comparative Examples 1-4, it can be seen that when any one of the raw materials is missing from the composition, its TRPV1 improvement rate is significantly reduced, indicating that there is a significant synergistic effect among the above four raw materials. Furthermore, comparing the results of Example 1 and Comparative Example 5, it can be seen that the composition obtained by mixing the four raw materials in the mass ratio specified in this invention can further improve the TRPV1 improvement rate of the composition.

[0076] Test Example 2: Cell experiments demonstrated that the composition has a soothing effect.

[0077] Test samples: Examples 1-7, Comparative Examples 1-5.

[0078] Experimental methods: The cell line used was mouse mononuclear macrophage leukemia cell line RAW264.7 (Wuhan Pronosei Life Science Technology Co., Ltd.). The test conditions were: incubator temperature 37±1℃, humidity 90±5%, carbon dioxide 5±1%. Cells were cultured and treated according to groups, followed by testing. The specific test was the detection of the inflammatory factor IL-6 content, and the test method is as follows:

[0079] (1) Seed the cell suspension into 12-well cell culture plates at a density of 5 × 10⁶ cells per well. 4 Add 100 μL of DMEM medium (2105341, Gibco) to each well and incubate for 24 h;

[0080] (2) Discard the liquid in the wells. Add 100 μL of DMEM medium containing 1 μg / mL lipopolysaccharide (LPS) to the control group. Add 100 μL of DMEM medium containing 1 μg / mL lipopolysaccharide (LPS) and 0.005 wt% of the test sample to the experimental group respectively. Set up 6 parallel replicates in each group and continue to culture for 24 h.

[0081] (3) Detection of inflammatory factor IL-6 content: The content of inflammatory factor IL-6 released by cells in culture medium was detected using a human IL-6 ELISA kit (catalog number EHC007.96, Shenzhen Xinbosheng Biotechnology Co., Ltd.). The specific operation was to take equal amounts of supernatant and add them to the corresponding reaction wells of the kit. After incubation, washing, and color development, the absorbance OD value was measured at a specific wavelength using an ELISA reader. The content of inflammatory factor IL-6 in each group was calculated according to the standard curve.

[0082] Interleukin-6 (IL-6) is a key pro-inflammatory cytokine. Abnormally elevated levels in the skin can trigger a series of negative effects: it directly promotes acute-phase reactions and persistent inflammation, recruiting more immune cells to infiltrate; at the same time, it disrupts the skin barrier function, inhibits keratinocyte differentiation, and reduces the expression of key barrier proteins, ultimately leading to problems such as skin sensitivity and redness.

[0083] The immunomodulatory capacity of the composition is represented by the improvement in the inflammatory factor IL-6, as shown in the following formula:

[0084] IL-6 improvement rate / % = (1 - IL-6 content sample group / IL-6 content control group) × 100%;

[0085] The results are shown in Table 4:

[0086] Table 4. Effect of Examples and Comparative Examples on IL-6 Improvement Rate

[0087]

[0088]

[0089] According to the results in Table 4, comparing the results of Examples 1-7, it can be seen that the combined use of schisandrin A, dihydroquercetin, senna glycoside, and panthenol in this invention can improve the improvement rate of IL-6. Comparing the results of Example 1 and Comparative Examples 1-4, it can be seen that when any one of the raw materials is missing from the composition, the improvement rate of IL-6 is significantly reduced, indicating that there is a significant synergistic effect among the above four raw materials. Furthermore, comparing the results of Example 1 and Comparative Example 5, it can be seen that the composition obtained by mixing the four raw materials in the mass ratio specified in this invention can further improve the improvement rate of IL-6.

[0090] Test Example 3 and cell experiments demonstrate that the application case and the control case have a repairing effect.

[0091] Experimental methods:

[0092] The cell model used was a human 3D epidermal skin model (Guangdong Boxi Biotechnology Co., Ltd.). The testing conditions were: incubator temperature 37±1℃, saturated humidity, and carbon dioxide 5±1%. The 3D epidermal models were cultured and treated according to groups, followed by testing. Specifically, the filaggrin (FLG) content was determined using the following method:

[0093] (1) The 3D epidermal skin model was cultured using EpiGrowth medium (Guangdong Boxi Biotechnology Co., Ltd.);

[0094] (2) Apply 25 μL of 0.1% sodium dodecyl sulfate (Sigma) to the surface of the 3D epidermal skin model and incubate for 30 minutes;

[0095] (3) The blank control group was uniformly coated with 12.5 μL of the emulsion prepared in the blank application example, and the sample group was coated with 12.5 μL of the emulsion prepared in application examples 1-9 and control application examples 1-5, and cultured for 24 hours.

[0096] (4) Detection of filaggrin FLG content: After the culture, the test substance remaining on the model surface was washed with PBS solution (Biosharp). The tissue was lysed with RIPA cell lysis buffer containing protease inhibitor. The lysed sample was centrifuged at 12000g for 5 minutes. The supernatant was collected and the filaggrin FLG content in the supernatant of each group was detected using a human filaggrin (FLG) ELISA kit (catalog number BLL107115E, Baililai Biotechnology). The specific operation was to add equal amounts of supernatant to the corresponding reaction wells of the kit. After incubation, washing, and color development, the absorbance OD value was measured at a specific wavelength using an ELISA reader. The filaggrin FLG content of each group was calculated according to the standard curve.

[0097] Filaggrin (FLG) is an important molecule in the stratum corneum of human skin that connects keratin fibers. With the assistance of FLG monomers, keratin fibers aggregate regularly, forming a solid physical barrier on the outermost layer of the epidermis, thus strengthening the skin.

[0098] The increase rate of filaggrin in each example and comparative example was calculated using the following formula:

[0099] The increase rate of filaggrin (%) = (sample group - blank control group) / blank control group × 100%, where a higher filaggrin increase rate indicates a stronger repair effect of the sample; the results are shown in Table 5:

[0100] Table 5. Application Examples and Comparative Application Examples: Impact on FLG Increase Rate

[0101]

[0102]

[0103] As shown in Table 5, comparing the results of Application Examples 1-9 and 1-5, the soothing and repairing lotion of the present invention significantly improves the FLG increase rate. Specifically, according to the results of Application Examples 1-7, the soothing composition composed of schisandrin A, dihydroquercetin, kaempferol glycoside, and panthenol within the mass ratio range defined by the present invention has a certain effect on increasing the FLG increase rate. According to Application Examples 1, 8, and 9, as the proportion of the soothing composition in the lotion increases, the effect of the lotion on increasing the FLG increase rate also gradually increases. According to the results of Application Example 1 and Comparative Application Example 5, the soothing composition defined by the present invention has the best effect on increasing the FLG increase rate when each ingredient is within the mass ratio range defined by the present invention. According to the results of Application Example 1 and Comparative Application Examples 1-4, when one ingredient in the composition of the present invention is missing, the human efficacy test results are poor, indicating that there is a significant synergistic effect among the four ingredients in the composition, which is consistent with the aforementioned efficacy experiments.

[0104] Test Example 4: Human Skin Patch Test.

[0105] Sixty volunteers were recruited, 30 men and 30 women, aged 20-50 years, and randomly divided into two groups of 15 men and 15 women each. A closed patch test was used. Equal volumes (0.020 mL-0.025 mL) of the test samples (emulsions prepared in Application Examples 1-9, Control Examples 1-5, and the blank application example) were placed in a specific patch applicator. The patch was then applied to the volunteer's arm with hypoallergenic adhesive tape, gently pressed to ensure even application, and left for 24 hours. The blank control group used distilled water, and the blank application example used an emulsion without the soothing composition. One patch applicator was applied to each arm of each volunteer. Each patch applicator had 10 wells, allowing for the simultaneous testing of 20 samples per volunteer (both arms). The first group used emulsions prepared in Application Examples 1-9 and the blank application example, while the second group used emulsions prepared in Control Examples 1-5 and the blank application example. A blank control was included in each group. After 24 hours, the patch applicator was removed. Skin reactions were observed at 0.5 hours, 24 hours, and 48 hours, and the results were recorded. The severity of adverse skin reactions is shown in Table 6 below.

[0106] Table 6 Adverse Reaction Grades

[0107]

[0108] After testing, the lotions provided in Application Examples 1-9, Comparative Application Examples 1-5, and Blank Application Examples of the present invention all showed negative reactions after human patch testing, indicating that they are safe and non-irritating to human skin.

[0109] Test Example 5: Human efficacy test of the composition in moisturizing, soothing, and repairing.

[0110] Experimental Methods: Ninety Asian adults aged 18-60 years with self-reported skin sensitivity were randomly divided into 15 groups of 6 participants each. Volunteers applied the sample to their entire face twice daily, morning and evening (the sample consisted of lotions prepared from Application Examples 1-9, Control Application Examples 1-5, and the blank application example). Data were collected before use (D0) and 7 days after use (D7). After arriving at the trial site, volunteers washed their faces with facial cleanser and sat quietly for 30 minutes in an air-conditioned room at 21±1℃ and 50±10% humidity. Researchers then measured the skin moisture content of the cheekbones using a Corneometer skin moisture meter. Facial images of the volunteers were taken using a Visia-7 camera, and image analysis was performed on the exported red area images to obtain the a* value. A skin moisture loss test probe (…) was used… Transdermal water loss (TEWL) of the cheekbone was measured using TM Hex; the percutaneous electrical sensory threshold (CPT, 5 Hz) of the cheek was measured using a sensory nerve quantitative detector (NEUROMETER CPT / C).

[0111] Skin moisturizing ability is represented by the improvement in skin moisture content; skin soothing ability is represented by the improvement in a* value; skin barrier repair ability is represented by the improvement in TEWL value; and the ability to increase the skin's nerve tolerance threshold is represented by the improvement in CPT value. The formulas are as follows:

[0112] Skin moisture content improvement rate = [(samples)] D7 -sample D0 ) / sample D0 -(Blank Application Example) D7 - Blank application example D0 ) / Blank Application Example D0 ×100%.

[0113] a* value improvement rate = [(samples)] D0 -sample D7 ) / sample D0 -(Blank Application Example) D0 - Blank application example D7 () / Blank application example D0]×100%.

[0114] TEWL value improvement rate = [(samples)] D0 -sample D7 ) / sample D0 -(Blank Application Example) D0 - Blank application example D7 ) / Blank Application Example D0 ×100%.

[0115] CPT value improvement rate = [(sample D7 -sample D0 ) / sampleD0 -(Blank Application Example) D7 - Blank application example D0 ) / Blank Application Example D0 ×100%.

[0116] The results were averaged, as shown in Table 7.

[0117] Table 7. Application Examples and Comparative Examples: Human Efficacy Test Results

[0118]

[0119] As shown in Table 7, compared with Application Examples 1-9 and 1-5, the emulsion with soothing and repairing effects of the present invention has good soothing and repairing effects. Specifically, according to the results of Application Examples 1-7, the soothing composition composed of schisandrin A, dihydroquercetin, kaempferol glycoside, and panthenol within the mass ratio range defined by the present invention has certain soothing and repairing effects. According to Application Examples 1, 8, and 9, as the proportion of the soothing composition in the emulsion increases, the soothing and repairing effects of the emulsion also gradually increase. According to the results of Application Example 1 and Comparative Application Example 5, the soothing and repairing effects achieved by each ingredient in the soothing composition defined by the present invention are optimal within the mass ratio range defined by the present invention. According to the results of Application Example 1 and Comparative Application Examples 1-4, when only one ingredient in the composition of the present invention is used, the human efficacy test results are poor, indicating that there is a significant synergistic effect among the four ingredients in the composition, which is consistent with the aforementioned efficacy experiments. Figure 1 Comparison photos of facial redness areas analyzed by VISIA-CR instrument after volunteers in Application Example 1 and the blank application example used the product for 7 days.

[0120] The embodiments described above are some, but not all, of the embodiments of this application. The detailed description of the embodiments of this application is not intended to limit the scope of the claimed application, but merely to illustrate selected embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of this application without inventive effort are within the scope of protection of this application.

Claims

1. A soothing composition, characterized in that, The composition comprises the following raw materials: schisandrin A, dihydroquercetin, senna glycoside, and panthenol; the mass ratio of schisandrin A, dihydroquercetin, senna glycoside, and panthenol is (0.01-3):(0.01-1):(0.01-1):(0.1-5).

2. The soothing composition according to claim 1, characterized in that, The mass ratio of schisandrin A, dihydroquercetin, senna glycoside, and panthenol is (0.1-1):(0.05-0.5):(0.05-0.5):(0.5-3).

3. The soothing composition according to claim 1, characterized in that, The mass ratio of schisandrin A, dihydroquercetin, senna glycoside, and panthenol is (0.3-0.5):(0.1-0.2):(0.1-0.2):(1-1.5).

4. The soothing composition according to claim 1, characterized in that, The mass ratio of schisandrin A, dihydroquercetin, senna glycoside, and panthenol is 0.4:0.15:0.15:1.

3.

5. The use of the soothing composition according to any one of claims 1-4 in the preparation of cosmetics with soothing and repairing effects.

6. The application according to claim 5, characterized in that, The cosmetic dosage form is any one of toner, lotion, cream, mask, serum, or spray.

7. A lotion with soothing and repairing effects, characterized in that, The emulsion comprises the soothing composition according to any one of claims 1-4.

8. The emulsion according to claim 6, characterized in that, The emulsion also includes at least one of the following: thickener, humectant, pH adjuster, emulsifier, preservative, and solvent.

9. The emulsion according to claim 8, characterized in that, Includes the following components by mass percentage: The soothing composition according to any one of claims 1-4: 1-4%; Thickener: 0.05-0.3%; Moisturizer: 0.5-3%; pH adjuster: 0.01-0.3%; Emulsifier: 0.5-5%; Preservatives: 0.5-3%; Solvent balance.

10. The emulsion according to claim 8, characterized in that, The thickener includes at least one of the following: polyacrylate crosspolymer-6, carbomer, carrageenan, gellan gum, xanthan gum, microcrystalline cellulose, cellulose gum, ethyl cellulose, prickly ash gum, guar gum, ammonium acryloyl dimethyl taurate / VP copolymer, acrylate copolymers, and sclerotium gum; the humectant includes glycerin, 1,2-butanediol, 1,3-butanediol, 1,2-hexanediol, 1,3-propanediol, caprylyl glycol, dipropylene glycol, tremella polysaccharide, trehalose, betaine, allantoin, sodium hyaluronate, β-glucan, budding stalk polysaccharide, and ceramide. At least one of the following: the pH adjuster includes at least one of arginine, tromethamine, and disodium EDTA; the emulsifier includes at least one of caprylic / capric triglyceride, C14-22 alcohol, C12-20 alkyl glucoside, sodium polyacrylate, hydrogenated lecithin, cetearyl glucoside, isononyl isononanoate, pentaerythritol tetraester, polydimethylsiloxane, stearyl alcohol, hydroxystearic acid, polymethylsilsesquioxane, pentaerythritol distearate, and sucrose stearate; the preservative includes at least one of p-hydroxyacetophenone and polyols; and the solvent is deionized water.

Images